PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed metastatic carcinoid tumor or islet cell tumor
• * Well-differentiated neuroendocrine tumor OR
• * Well-differentiated neuroendocrine carcinoma
• Measurable disease in at least 1 dimension
• * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• * The following are considered nonmeasurable:
• * Lesions in a previously irradiated area
• * Bone lesions
• * Leptomeningeal disease
• * Ascites
• * Pleural/pericardial effusion
• * Lymphangitis cutis/pulmonis
• * Abdominal masses that are not confirmed and followed
• * Cystic lesions
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 6 months
• Hematopoietic:
• Leukocyte count at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• AST/ALT no greater than 2.5 times upper limit of normal
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular:
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other:
• No other uncontrolled illness
• No ongoing active infection
• No psychiatric illness or social situation that would preclude study
• No history of allergic reaction to compounds of similar chemical or biologic composition to bortezomib
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior immunotherapy (interferon alfa)
• Chemotherapy:
• No more than 1 prior systemic chemotherapy regimen (except hepatic artery chemoembolization)
• At least 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas)
• At least 12 weeks since prior hepatic artery chemoembolization (unless liver lesions are not indicator lesions)
• Stable dose long-acting octreotide therapy (Sandostatin LAR) within the past 3 months allowed
• Concurrent subcutaneous octreotide for breakthrough symptomatic relief allowed
• Endocrine therapy:
• Not specified
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• Surgery:
• Not specified
• Other:
• No other concurrent investigational agents, commercial agents, or therapies
• No concurrent combination antiretroviral therapy for HIV-positive patients